Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1994-07-07
1996-11-12
Walsh, Stephen G.
Chemistry: molecular biology and microbiology
Spore forming or isolating process
435 691, 424 9321, C12N 510
Patent
active
055739407
ABSTRACT:
A method and means for protecting cells and transplanted organs for the effects of activated complement proteins generated in blood serum or plasma by introducing the gene for CD59 into the cells to be protected is described. In an example of the method, protection against the pore-forming activity of the human C5b-9 proteins was conferred on CHO cells by transfection with cDNA encoding the human complement regulatory protein CD59.
REFERENCES:
patent: 4447415 (1984-05-01), Rock et al.
patent: 4695460 (1989-09-01), Holme
patent: 4916219 (1990-04-01), Linhardt et al.
patent: 5109113 (1992-04-01), Caras
patent: 5179198 (1993-06-01), Okada
Sawada et al "Isolation and Expression of the Full-Length cDNA Encoding CD59 Antigen of Human Lymphocytes", DNA Cell Biol. 9(3):213-220 (Apr. 1990).
Caras et al "Signal for Attachment of a Phospholipid Membrane Anchor . . . " Science 238:1280-1283 (Nov. 1987).
Sambrook et al "Molecular Cloning: A Laboratory Manual." Cold Spring Harbor Laboratory Press (1989), pp. 16.1-16.72.
"Soluble Forms of CD59-Antigen Distribution in Body Fluids and Functional Activity," 65 Complement Inflammation 193 (1991) Abstract.
Rooney, I. A., and Morgan, B. P., "Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid," 76 Immunology 541-547 (1992).
Davies, Alexandra, et al., "CD59, An Ly-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells," 170 J. Exp.Med. 637-654 (Sep. 1989).
Bevers, E. M., et al., "Defective microvesiculation and deficient expression of procoagulant activity in Scott syndrome red blood cells," Amer. Soc. Hematology 33rd Annual Meeting, abstract No. 319, 78 Blood (Supp 1) 82a (1991).
Bevers, E. M., et al., "Defective Ca.sup.2+ -induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of Scott syndrome," 79 Blood 380-388 (Jan. 15, 1992).
Braga, L., et al., "A monoclonal antibody to the galactose-specific adhesin abrogates the resistance of E. histolytica to lysis by human complement CSb-9," XIV International Complement Workshop, Cambridge, U.K. (1991), abstract No. 24, 8 Complement & Inflammation 131 (1991).
Chang, C.-P., et al., "Contribution of platelet microparticle formation and granule secretion to the transbilayer migration of phosphatidylserine," Amer. Soc. Hematology 33rd Annual Meeting, abstract No. 1569, 78 Blood (Supp 1) 395a (1991).
Cheng K.-H. et al., "Fluorescence resonance energy transfer study of the associative state of membrane-bound complexes of complement proteins C5b-8," 135 J. Immunol. 459-464 (1985).
Davies, A., et al., "CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells," 170 J. Exp. Med. 637-654 (Sep. 1989).
Hahn, W. C., et al., "Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59," 256 Science 1805-1807 (1992).
Hamilton, K. K., et. al., "Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex," 265 J. Biol. Chem. 3809-3814 (Mar. 1990).
Hamilton, K. K., et al., "Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59," 76 Blood 2572-2577 (Dec. 1990).
Hamilton, K. K., and P. J. Sims, "The terminal complement proteins C5b-9 augment binding of high density lipoprotein and its apolipoproteins A-I and A-II to human endothelial cells," 88 J. Clin. Invest. 1833-1840 (Dec. 1991).
Holguin, M. H., et al., "Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria," 84 J. Clin. Invest. 7-17 (Jul. 1989).
Lin, R. C., et al., "A family showing inheritance of the Inab phenotype," 28 Transfusion 427-429 (1988).
Lublin, D. M., and J. P. Atkinson, "Decay-accelerating fator and membrane cofactor protein," 153 Curr. Top. Microbiol. Immunol. 123-145 (1989).
Medof, M. E., et al., "Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes," 160 J. Exp. Med. 1558-1578 (Nov. 1984).
Menu, E., et al., "Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand, CD59," abstract No. 1665, 6 FASEB 1224 (1992).
Ninomiya, H., et al., "Contribution of N-linked carbohydrate to the complement-inhibitory function of CD59," Amer. Soc., Hematology 33rd Annual Meeting, abstract No. 1375, 78 Blood (Suppl 1) 346a (1991).
Ninomiya, H., et al., "Specific binding of complement inhibitor CD59 to C8.alpha. & to the b domain of C9," abstract No. 2980, 6 FASEB J. 1224 (1992).
Ninomiya, H., et al., "Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity," 267 J. Biol. Chem. 8404-8410 (1992).
Ninomiya, H., and P. J. Sims, "The human complement regulatory protein CD59 binds to the .alpha.-subunit of C8 and the b domain of C9," 267 J. Biol. Chem. 13675-13680 (Jun./Jul. 1992).
Okada, H., et al., "20 KDa homologous restriction factor of complement resembles T cell activating protein," 162 Biochem. Biophys. Res. Commun. 1553-1559 (1989).
Philbrick, W. M., et al., "The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility," 20 Eur. J. Immunol. 87-92 (1990).
Platt, J. L., et al., "Transplantation of discordant xenografts: a review of progress," 11(12) Immunol. Today 450-456 (1990).
Rollins, S. A., and P. J. Sims, "The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9," 144 J. Immunol. 3478-3483 (May 1990).
Sawada, R., et al., "Complementary DNA sequence and deduced peptide sequence for CD59/MEM-43 antigen, the human homologue of murine lymphocyte antigen Ly-6C," 17 (16) Nucleic Acids Res. 6728 (1989).
Schonermark, S., et al., "Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor," 136 J. Immunol. 1772-1776 (1986).
Sims, P. J., "Complement protein C9 labeled with fluorescein isothiocyanate can be used to monitor C9 polymerization and formation of the cytolytic membrane lesion," 23 Biochemistry 3248-3269 (1984).
Sims, P. J., et al., "Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane: Studies in Scott syndrome: An isolated defect in platelet procoagulant activity," 264 J. Biol. Chem. 17049-17057 (Oct. 1989).
Sims, P. J., et al., "Regulatory control of complement on blood platelets: Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex," 264 J. Biol. Chem. 19235-19235 (Nov. 15, 1989).
Slanetz, A. E., and A. L. M. Bothwell, "Heterodimeric, disulfide-linked .alpha./.beta. T cell receptors in solution," 21 Eur. J. Immunol. 179-183 (Jan. 1991).
Stefanova, I., et al., "Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol," 26 Molec. Immunol. 152-161 (1989).
Sugita, Y., et al., "Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels," 104 J. Biochem. 633-637 (1988).
Takebe, Y., et al., "SR.alpha. promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat," 8 Molec. Cell. Biol. 466-472 (1988).
Telen, M. J., et al., "Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF," 167 J. Exp. Med. 1993-1998 (Jun. 1988).
Walsh, L. A., et al., "Transfection of human CD59 complementary DNA into rat cells confers resistance to hu
Bothwell Alfred L. M.
Sims Peter J.
Oklahoma Medical Research Foundation
Walsh Stephen G.
Yale University
LandOfFree
Cells expressing high levels of CD59 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cells expressing high levels of CD59, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cells expressing high levels of CD59 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-561868